We are a financial services provider for several types of professional clients, each with distinct needs.
BUSINESS ACCOUNT
Access reports individually or via Subscription
Receive monthly invoices with payment via CSA or hard dollars
Analyst access
Free Trial Subscriptions
Team account with shared subscriptions
Advanced analytics to track research consumption and performance
We increased our Target Price for Biotalys to € 7.5 (was €6.1) while maintaining our Buy rating after Biotalys announced that the US EPA (Environmental Protection Agency) has issued its proposed registration decision to approve its first biofungicide, Evoca. The EPA will now initiate the final phase in its regulatory review, allowing stakeholders such as growers and industry associations 15 days to provide feedback before finalizing its regulatory decision. The EPA has also posted a final rule e...
Eurocommercial reports results in line with our expectations at EUR 1.85 direct investment result per share vs. 1.83 KBCSe (+1.1% YoY). The rental income growth accelerated at 3.6% like-for-like (1.7% above inflation) driven by rent reversion, stable (+10bps) vacancy and higher retail sales (+4.1% vs 2.6% in 1H25). The like-for-like growth is mainly driven by the Italian portfolio at +5.1%. The average rent collection dropped from 99.0% to 98.0% coming from the French portfolio (92% in 3Q25). Th...
3Q25 figures showed overall revenues falling -12.6% to €505m well below forecasts. Thanks to solid cost control EBIT landed at €65m considerably above our €51mE and €43m CSS fcst. Following three profit warnings expectations were likely not overly challenging. Given the deep discount valuation we believe today's share price reaction is not necessarily a prelude for 2026 performance. A positive reaction will likely follow but a structural re-rating will only occur once there are clear indications...
The announced divestment of the Oil & Gas business unit to SNF was no surprise, as this business had been earmarked previously as non-core and did not fit well with the ESG profile and profitability margins of the remainder of the group. The transaction is fairly small though, with an EV of € 135m. Despite the weak current earnings momentum at Syensqo, we believe that cost efficiency measures and further portfolio streamlining (also Aroma Performance is considered non core) should eventually be ...
Rising interest rates are becoming a hot topic, triggered by a significant uptick in US 10-year treasury yields through February and March. In this note we revisit this topic from several angles. We dig into the empirical side of what we can reasonably expect from the market as a whole when interest rates start to rise. Secondly we review our coverage, putting forward a number of impacted sectors and stocks.